Source: Pharmacy Times articles
The Version 3.2025 update adds tislelizumab-based regimens as preferred first-line treatments and introduces new dosing schedules for PD-L1–positive esophageal squamous cell carcinoma.
Read More
by MM360 Staff | Apr 23, 2025 | Myeloma News | 0 comments
Source: Pharmacy Times articles
The Version 3.2025 update adds tislelizumab-based regimens as preferred first-line treatments and introduces new dosing schedules for PD-L1–positive esophageal squamous cell carcinoma.
Read More